it is designed to provide a massive foundational dose of genomic and structural matrix support (via GHK-Cu) while delivering potent, equipotent clinical doses of acute inflammatory modulators and cellular migration catalysts (via BPC-157 and TB-500)
The first demonstration that DPP-4 inhibition reduces blood glucose levels in type 2 diabetes was published in 2002 [36]
Compared to patients treated for diabetes with a non-GLP-1 medication, GLP-1 use was associated with 14% reduced risk of developing any substance use disorder
Always easy to do business with products are great
The profound exhaustion, the racing heart upon standing, and the thick, suffocating "brain fog" are hallmarks of complex chronic conditions like Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), and dysautonomia
doi: 10.1016/S1074-5521(02)00129-1